ライフサイエンスコーパス: macular degeneration

1 ients with subfoveal neovascular age-related macular degeneration).

2 isual outcomes for patients with age-related macular degeneration.

3 n eye diseases like glaucoma and age-related macular degeneration.

4 tis pigmentosa (RP) and atrophic age-related macular degeneration.

5 liferative vitreoretinopathy and age-related macular degeneration.

6 ve effect of FHR-1 deficiency in age-related macular degeneration.

7 lassification of Age-related Maculopathy and Macular Degeneration.

8 olamine elimination in a cell-based model of macular degeneration.

9 in eyes with advanced stages of age-related macular degeneration.

10 f Toll-like receptor 2 (TLR2) in age-related macular degeneration.

11 macular degeneration (AMD) and 2 with myopic macular degeneration.

12 egenerative disorders, including age-related macular degeneration.

13 signaling in the pathogenesis of age-related macular degeneration.

14 ome and C3 glomerulopathies, and age-related macular degeneration.

15 ve relevance for the etiology of age-related macular degeneration.

16 n many patients with neovascular age-related macular degeneration.

17 loss in diabetic retinopathy and age-related macular degeneration.

18 tis pigmentosa (RP) and atrophic age-related macular degeneration.

19 on and shows symptoms similar to age-related macular degeneration.

20 erative diabetic retinopathy and age-related macular degeneration.

21 gene commonly cause retinal dysfunction and macular degeneration.

22 ve diabetic retinopathy, and wet age-related macular degeneration.

23 ity, but patients still progressed to severe macular degeneration.

24 omatopsia, cone dystrophies, and early onset macular degeneration.

25 refractive error, cataracts, and age-related macular degeneration.

26 ed retinoschisis (XLRS), a monogenic form of macular degeneration.

27 cently reported association with age-related macular degeneration.

28 rs such as Stargardt disease and age-related macular degeneration.

29 he assimilation of lutein in humans to avoid macular degeneration.

30 t disease and the ocular disease age-related macular degeneration.

31 rosis development in neovascular age-related macular degeneration.

32 ambiguity about cone survival in age-related macular degeneration.

33 eatment regimens for neovascular age-related macular degeneration.

34 in the management of neovascular age-related macular degeneration.

35 's membrane alterations, such as age-related macular degeneration.

36 asked how these are compromised in models of macular degeneration.

37 patients (n = 14) showed early and extensive macular degeneration.

38 , including Behcet's disease and age-related macular degeneration.

39 inal dystrophy that is accompanied by severe macular degeneration.

40 apeutic approach for neovascular age-related macular degeneration.

41 her macular disease including AMD and myopic macular degeneration.

42 mes and drives the pathogenesis of Stargardt macular degeneration.

43 tients with advanced neovascular age-related macular degeneration.

44 ive diabetic retinopathy and wet age-related macular degeneration.

45 ould be effective therapeutic approaches for macular degenerations.

46 site of injury in inherited and age-related macular degenerations.

47 ith no sex difference related to age-related macular degeneration (0.91 [0.70-1.14]).

48 r (61.3%), cataract (13.2%), and age-related macular degeneration (10.3%).

49 served in 55.6 % of photographs (age-related macular degeneration: 34.2 %; diabetic retinopathy: 4.2

50 or glaucoma (63.4%); only half were aware of macular degeneration; 37.3% were aware of diabetic retin

51 Age-related macular degeneration 4 included neovascular AMD (nvAMD)

52 ilable for cataract surgery (10 metrics) and macular degeneration (7 metrics).

53 ve participants with neovascular age-related macular degeneration, 7 of whom were treatment naive.

54 Nystagmus (64%), strabismus (52%), macular degeneration (72%), optic nerve pallor (68%), an

55 18.2 million to 109.6 million]), age-related macular degeneration (8.4 million [0.9 million to 29.5 m

56 Age-related macular degeneration according to fundus photographs gra

57 either persistent amblyopia and age-related macular degeneration (AMB + AMD), or with bilateral age-

58 Age-related macular degeneration (AMD) affects millions of people th

59 Age-related macular degeneration (AMD) affects the retinal pigment e

60 Although numerous common age-related macular degeneration (AMD) alleles have been discovered

61 for the treatment of neovascular age-related macular degeneration (AMD) among Medicare beneficiaries.

62 geographic atrophy secondary to age-related macular degeneration (AMD) and 2 eyes (5%) had geographi

63 s were diagnosed with coincident age-related macular degeneration (AMD) and 2 with myopic macular deg

64 tients with AVLs associated with age-related macular degeneration (AMD) and adult-onset foveomacular

65 aHUS), also confers high risk of age-related macular degeneration (AMD) and associates with C3 glomer

66 tic reviews of interventions for age-related macular degeneration (AMD) and described the main findin

67 ociations between early and late age-related macular degeneration (AMD) and neovascular AMD (nvAMD) w

68 Age-related macular degeneration (AMD) and proliferative diabetic re

69 Age-related macular degeneration (AMD) and related macular dystrophi

70 ges of patients with neovascular age-related macular degeneration (AMD) and to demonstrate its use to

71 non-neovascular and neovascular age-related macular degeneration (AMD) and to provide recommendation

72 scularization (CNV) secondary to age-related macular degeneration (AMD) and VA between 20/25 and 20/3

73 icity on the association between age-related macular degeneration (AMD) and vision-specific functioni

74 available treatment options for age-related macular degeneration (AMD) are limited, particularly for

75 ecline in the risk of developing age-related macular degeneration (AMD) continued for people born dur

76 gene and their association with age-related macular degeneration (AMD) have been described.

77 g cardinal features of human dry age-related macular degeneration (AMD) in 12-month-old male and fema

78 year incidence of early and late age-related macular degeneration (AMD) in a Singaporean Malay popula

79 ve eyes diagnosed with exudative age-related macular degeneration (AMD) in comparison with eyes with

80 terranean diet and prevalence of age-related macular degeneration (AMD) in countries ranging from Sou

81 incidence of intermediate-stage age-related macular degeneration (AMD) in patients with acquired imm

82 drusen, and the presence of late age-related macular degeneration (AMD) in the fellow eye.

83 The genetic architecture of age-related macular degeneration (AMD) involves numerous genetic var

84 Age-related macular degeneration (AMD) is a frequent, complex disord

85 Age-related macular degeneration (AMD) is a leading cause of blindne

86 Age-related macular degeneration (AMD) is a leading cause of irrever

87 Age-related macular degeneration (AMD) is a leading cause of irrever

88 Age-related macular degeneration (AMD) is a major cause of blindness

89 Age-related macular degeneration (AMD) is a major cause of blindness

90 Age-related macular degeneration (AMD) is a major cause of irreversi

91 Age-related macular degeneration (AMD) is a major cause of visual im

92 Importance: Age-related macular degeneration (AMD) is a multifactorial disease w

93 Age-related macular degeneration (AMD) is a progressive blinding dis

94 Age-related macular degeneration (AMD) is a progressive retinal neur

95 Neovascular age-related macular degeneration (AMD) is characterized by choroidal

96 Age-related macular degeneration (AMD) is the leading cause of blind

97 Advanced age-related macular degeneration (AMD) is the leading cause of blind

98 Age-related macular degeneration (AMD) is the leading cause of irrev

99 Age-related macular degeneration (AMD) is the most common cause of b

100 ed omega-3 (n-3) fatty acid, and age-related macular degeneration (AMD) is unclear.

101 The incidence of age-related macular degeneration (AMD) is unknown in Africa.

102 on-based prevalence estimates of age-related macular degeneration (AMD) need to be determined to asse

103 To evaluate the impact of age-related macular degeneration (AMD) on short out-loud and sustain

104 used by persistent amblyopia and age-related macular degeneration (AMD) or by bilateral AMD, had an a

105 d (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control eyes, as we

106 Three controls without age-related macular degeneration (AMD) or retinal disease at fundus

107 uated for protection against wet age-related macular degeneration (AMD) over a 6month period followin

108 , 1 from a 78-year-old exudative age-related macular degeneration (AMD) patient, 1 from a 58-year-old

109 ascularization (NV) in eyes with age-related macular degeneration (AMD) receiving anti-vascular endot

110 in diabetic retinopathy (DR) and age-related macular degeneration (AMD) remains unclear.

111 -function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD sub-phenoty

112 redictors of lipid fractions and age-related macular degeneration (AMD) risk.

113 LLQ) in patients with a range of age-related macular degeneration (AMD) severity are associated with

114 subset of eyes with neovascular age-related macular degeneration (AMD) that have persistent exudatio

115 ophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to progressive and

116 y (GA) secondary to nonexudative age-related macular degeneration (AMD) through multimodal imaging.

117 ome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevaci

118 anatomic outcome in neovascular age-related macular degeneration (AMD) treated with as-needed ranibi

119 al evaluating progression of dry age-related macular degeneration (AMD) using color photographs at an

120 bolomic profile of patients with age-related macular degeneration (AMD) using mass spectrometry (MS).

121 y choriocapillaris blood flow in age-related macular degeneration (AMD) using optical coherence tomog

122 igment epithelium (RPE) cells in age-related macular degeneration (AMD) using polarimetry.

123 Most classification systems for age-related macular degeneration (AMD) were developed from patients

124 standard care for patients with age-related macular degeneration (AMD) who are being considered for

125 ls for the study of nonexudative age-related macular degeneration (AMD) with an emphasis on a novel c

126 y SD OCT study participants with age-related macular degeneration (AMD) with bilateral large drusen o

127 pants with at least intermediate age-related macular degeneration (AMD) with control subjects without

128 t; 62.7% were performed to treat age-related macular degeneration (AMD), 16.1% to treat diabetic reti

129 iking phenotypic similarities to age-related macular degeneration (AMD), a common and genetically com

130 capillaris are characteristic of age-related macular degeneration (AMD), a common vision-threatening

131 Age-related macular degeneration (AMD), a leading cause of vision im

132 Age-related macular degeneration (AMD), a leading contributor of vis

133 H), show strong association with age-related macular degeneration (AMD), a major cause of blindness.

134 Age-related macular degeneration (AMD), a multifactorial disease wit

135 nt factor in the pathogenesis of age-related macular degeneration (AMD), although direct evidence for

136 have implicated AP activation in age-related macular degeneration (AMD), and AP dysfunction predispos

137 h visual acuity (VA) impairment, age-related macular degeneration (AMD), and cataract surgery.

138 f the importance of nutrition in age-related macular degeneration (AMD), but few studies have explore

139 zation (CNV) among patients with age-related macular degeneration (AMD), but no economic evaluation h

140 To test potential treatments for age-related macular degeneration (AMD), clinical trials need standar

141 opathy (PCV), a subtype of 'wet' age-related macular degeneration (AMD), constitutes up to 55% of cas

142 Other diseases, such as age-related macular degeneration (AMD), develop late in life and are

143 imer's disease, hemochromatosis, age-related macular degeneration (AMD), diabetes mellitus, and cysti

144 ls for management of neovascular age-related macular degeneration (AMD), diabetic macular edema (DME)

145 rse range of diseases, including age-related macular degeneration (AMD), glaucoma and refractive erro

146 Patients with age-related macular degeneration (AMD), myopia, pachychoroid disease

147 In age-related macular degeneration (AMD), rare variants in the complem

148 es including dry and neovascular age-related macular degeneration (AMD), retinitis pigmentosa, and di

149 ular pathologies in the eye like age-related macular degeneration (AMD), the diabetic retinopathie (D

150 eration, a subset of neovascular age-related macular degeneration (AMD), which is associated with hig

151 uited patients with intermediate age-related macular degeneration (AMD), without other vitreoretinal

152 examine their associations with age-related macular degeneration (AMD)-related features and AMD prog

153 lation, of physical activity and age-related macular degeneration (AMD)-the main cause of irreversibl

154 tory marker associated with late age-related macular degeneration (AMD).

155 ermediate and advanced stages of age-related macular degeneration (AMD).

156 aflibercept to treat neovascular age-related macular degeneration (AMD).

157 ibute to the oxidative stress in Age-related macular degeneration (AMD).

158 s from images from patients with Age-related Macular Degeneration (AMD).

159 H (CFH) confer greater risk for age-related macular degeneration (AMD).

160 otect against the development of age-related macular degeneration (AMD).

161 raphic atrophy (GA) secondary to age-related macular degeneration (AMD).

162 as diabetic retinopathy (DR) and age-related macular degeneration (AMD).

163 tial role in the pathogenesis of age-related macular degeneration (AMD).

164 aging) in eyes with nonexudative age-related macular degeneration (AMD).

165 idal neovascularization (CNV) in age-related macular degeneration (AMD).

166 ecursor to geographic atrophy in age-related macular degeneration (AMD).

167 f the risk of vision loss due to Age-Related Macular Degeneration (AMD).

168 n OCT findings in the setting of age-related macular degeneration (AMD).

169 contribute to the progression of age-related macular degeneration (AMD).

170 to the pathogenic progression of age-related macular degeneration (AMD).

171 tered in patients with exudative age-related macular degeneration (AMD).

172 upplementation on progression of age related macular degeneration (AMD).

173 conditions like RP and atrophic age-related macular degeneration (AMD).

174 he pathogenesis of inherited and age-related macular degeneration (AMD).

175 matory retinal disorders such as age-related macular degeneration (AMD).

176 flammation increases the risk of age-related macular degeneration (AMD).

177 ations in eyes with intermediate age-related macular degeneration (AMD).

178 intakes with a high incidence of age-related macular degeneration (AMD).

179 d lesions which are hallmarks of age-related macular degeneration (AMD).

180 o contribute the pathogenesis of age-related macular degeneration (AMD).

181 and C2 genes are associated with age-related macular degeneration (AMD); however, the association of

182 und to be highly associated with age-related macular degeneration (AMD); however, the effect on clini

183 mes of patients with neovascular age-related macular degeneration (AMD, n = 400), diabetic macular ed

184 e 4 most prevalent eye diseases (age-related macular degeneration [AMD], cataract, diabetic retinopat

185 g the normal and diseased state (age related macular degeneration, AMD) in the retina.

186 refractive error, cataracts, and age-related macular degeneration among adults 65 years or older in t

187 years or older with neovascular age-related macular degeneration and a baseline best-corrected visua

188 To identify GA in age-related macular degeneration and assess treatment, correlation o

189 To report patients with age-related macular degeneration and atypical central retinal pigmen

190 al degenerative diseases such as age-related macular degeneration and diabetic retinopathy.

191 es for retinal diseases, such as age-related macular degeneration and inherited retinal dystrophies,

192 in both eyes of adult mammals is a model for macular degeneration and leads to retinotopic map reorga

193 ss in many eye diseases, such as age-related macular degeneration and macular telangiectasia.

194 rse clinical disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobin

195 arget in a number of diseases, including wet macular degeneration and wound healing.

196 nant I62-CFH (protective against age-related macular degeneration) and V62-CFH functioned equivalentl

197 dema, 32 (25.8%) had neovascular age-related macular degeneration, and 32 (25.8%) had other causes of

198 es such as diabetic retinopathy, age-related macular degeneration, and central retinal vein occlusion

199 cted refractive error, glaucoma, age-related macular degeneration, and diabetic retinopathy).

200 ematurity, diabetic retinopathy, age-related macular degeneration, and glaucoma, as well as anticipat

201 uded aphakia, pseudophakia, late age-related macular degeneration, and vision impairment due to catar

202 tion of pure geographic atrophy or exudative macular degeneration, any type of drusen with pigmentary

203 regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settin

204 inal pigment epithelium (RPE) of age-related macular degeneration (ARMD) patients and therefore could

205 d with neovascularization in wet age-related macular degeneration (ARMD), choriocapillaris degenerati

206 n various pathologies, including age-related macular degeneration, arthritis, and cancer.

207 urity, diabetic retinopathy, and age-related macular degeneration, as well as corneal diseases with a

208 Age-related macular degeneration automated detection was applied to

209 n (AMB + AMD), or with bilateral age-related macular degeneration (BAMD).

210 cizumab injections for exudative age-related macular degeneration between January 1, 2009, and Decemb

211 Diseases such as macular degeneration can change visual sensory processin

212 f ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic retinopathy, g

213 ic atrophy is a blinding form of age-related macular degeneration characterized by retinal pigmented

214 s is an end stage of neovascular age-related macular degeneration, characterized by fibrous membrane

215 n mouse and human eyes, both normal and with macular degeneration/choroidal neovascularization.

216 dry eye syndrome) and posterior (age-related macular degeneration, diabetic retinopathy and glaucoma)

217 common, but serious, conditions: age-related macular degeneration (Dr. Fine), diabetic retinopathy (D

218 ould be of clinical and research interest in macular degeneration, for example in estimating visual p

219 ancestry from the International Age-related Macular Degeneration Genomics Consortium.

220 Ophthalmic diseases, such as age-related macular degeneration, glaucoma, and diabetic retinopathy

221 irment) and a high prevalence of age-related macular degeneration (>14% of blindness) as causes in th

222 eases associated with NAION were age-related macular degeneration (HR = 1.29; 95% CI: 1.08-1.54) and

223 (nGA) in eyes with intermediate age-related macular degeneration (iAMD).

224 etween plasma HDL-C and risk for age-related macular degeneration; (iii) only some mechanisms of lowe

225 tinoschisis (XLRS) is one of the most common macular degenerations in young males, with a worldwide p

226 ystallin plays multiple roles in age-related macular degeneration, including cytoprotection and angio

227 tic reviews of interventions for age-related macular degeneration incorporated into clinical practice

228 Neovascular age-related macular degeneration is among the most common causes of

229 Age related macular degeneration is the leading cause of blindness i

230 oschisis (XLRS), a leading cause of juvenile macular degeneration, is characterized by a spoke-wheel

231 The other, age-related macular degeneration, is the most common form of blindne

232 ly contributes to vision loss in age-related macular degeneration, is unclear.

233 Age-related macular degeneration may be more than a "macular" condit

234 participants with central vision loss due to macular degeneration (MD).

235 ies for vision-threatening disorders such as macular degeneration (MD).

236 el, Switzerland) for neovascular age-related macular degeneration (nAMD) after 2 years when using a t

237 monthly visits for patients with neovascular macular degeneration (nAMD) compared with monthly pro re

238 F-A in patients with neovascular age-related macular degeneration (nAMD) demonstrated dramatic benefi

239 mes in patients with neovascular age-related macular degeneration (nAMD) during anti-vascular endothe

240 ces of patients with neovascular age-related macular degeneration (nAMD) for different anti-vascular

241 ens in patients with neovascular age-related macular degeneration (nAMD) from the TReat and extEND (T

242 real aflibercept for neovascular age-related macular degeneration (nAMD) in routine clinical practice

243 he natural course of neovascular age-related macular degeneration (nAMD) is essential in discussing p

244 ment-naive eyes with neovascular age-related macular degeneration (nAMD) tracked by the Fight Retinal

245 VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a single anti-v

246 hy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ranibizumab.

247 among patients with neovascular age-related macular degeneration (nAMD) who participated in a large-

248 ths in patients with neovascular age-related macular degeneration (nAMD) with insufficient response t

249 patients treated for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME

250 with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DM

251 for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shift

252 apy in patients with neovascular age-related macular degeneration (nAMD).

253 oidal neovascularisation akin to age-related macular degeneration, NCD loss attenuated vessel leakage

254 Neovascular age-related macular degeneration (NVAMD) is the most common cause of

255 guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research investments

256 among patients with neovascular age-related macular degeneration (NVAMD) treated with anti-vascular

257 is for patients with neovascular age-related macular degeneration (nvAMD).

258 occlusion (RVO), and neovascular-age related macular degeneration (nvAMD).

259 nd (TAE) regimen for neovascular age-related macular degeneration (NVAMD).

260 Differences in progression and severity of macular degeneration, optic nerve pallor, and vascular a

261 When a patient with neovascular age-related macular degeneration or diabetic macular edema does not

262 When a patient with neovascular age-related macular degeneration or diabetic macular edema does not

263 mg injections of aflibercept for age-related macular degeneration or diabetic macular edema in a 9-me

264 nts for treatment of neovascular age-related macular degeneration or diabetic macular edema.

265 chronic retinal diseases such as age-related macular degeneration or diabetic macular edema.

266 nts for treatment of neovascular age-related macular degeneration or diabetic macular edema.

267 High myopia, age-related macular degeneration, or prostaglandin analog use were n

268 antly with sets found by GWAS of age-related macular degeneration (P=1.4 x 10(-12)), ulcerative colit

269 mer's disease (P=4.4 x 10(-15)), age-related macular degeneration (P=6.4 x 10(-6)), and Parkinson's d

270 that iPSC-derived RPE cells from age-related macular degeneration patients express increased levels o

271 emplary search for patients with age-related macular degeneration, performed cataract surgery, and at

272 In contrast to neovascular age related macular degeneration, polypoidal choroidal vasculopathy

273 ovascularization and neovascular age related macular degeneration presenting with hemorrhagic and exu

274 ATEMENT Central retinal lesions, a model for macular degeneration, result in functional reorganizatio

275 cclusion, macular hole, epiretinal membrane, macular degeneration, retinal detachment repair, and pro

276 diseases, of which the main are age-related macular degeneration, retinal vein occlusion and diabeti

277 ictions for proteins involved in age-related macular degeneration, retinitis pigmentosa, and Leber's

278 Recessive Stargardt macular degeneration (STGD1) is caused by mutations in t

279 urity, diabetic retinopathy, and age-related macular degeneration, threaten the visual health of chil

280 .9 million to 124.1 million), by age-related macular degeneration to 8.8 million (0.8 million to 32.1

281 diseases, including stroke, AD, age-related macular degeneration, traumatic brain injury, Parkinson'

282 e of blindness for patients with age-related macular degeneration, treat symptoms but not the underly

283 inical trials, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Di

284 inical trials, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) and the Di

285 ts enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), a randomi

286 articipants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

287 t study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

288 etic retinopathy and neovascular age-related macular degeneration, uncontrolled angiogenesis can lead

289 r inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire a snapshot o

290 final vision (P = .007), whereas age-related macular degeneration was associated with poorer vision (

291 Age-related macular degeneration was attributed as the main cause of

292 Acute macular degeneration was more common in men (10.9% [9.3%

293 tients with advanced neovascular age-related macular degeneration were enrolled in the study between

294 f 1097 patients with neovascular age-related macular degeneration were randomized to intravitreal ran

295 retinal injection in neovascular age-related macular degeneration (wet AMD) over 36 months.

296 rusenoid deposits, a hallmark of age-related macular degeneration, which is a common blinding disease

297 erent metrics for cataract surgery and 2 for macular degeneration, which showed only limited overlap

298 ur method to an in-depth GWAS of age-related macular degeneration with 33,976 individuals and 9,857,2

299 ented by patients with bilateral age-related macular degeneration with similar decrease of vision.

300 n oral treatment for neovascular age-related macular degeneration would be less burdensome than repea